Home > Drug List > Niraparib > Drug interactions of Niraparib

Drug interactions of Niraparib

Potent CYP3A4 Inhibitors

If co-administration is necessary, the dosage of revumenib should be reduced.

Potent or Moderate CYP3A4 InducersCo-administration with revumenib is not recommended.

Drugs That Prolong QTc Interval

Co-administration with revumenib is not recommended. If co-administration is unavoidable, more frequent monitoring for QTc interval prolongation in patients is required.

FDA，2025.10

Niraparib

Niraparib

Indications： It is indicated for the treatment of relapsed or refractory acute leukemia (with KMT2A translocation) or relapsed or refractory acute myeloid leukemia (with NPM1 mutation) in adult patients and pediat

Scan code
Whatsapp

Medicine-related columns

Recommended Articles

Related Articles

There is no data under this category！
Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More

Hospital Departments
Latest Articles
Medicine Updates

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.

Product

Product

Contact US

Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos

E-mail:laoslucius@gmail.com

Whatsapp:

Lucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved Lucius Pharmaceuticals Lucius

WhatsApp